Early viral and peripheral blood mononuclear cell responses to pegylated interferon and ribavirin treatment: The first 24h

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 10, 2010, Pages 1211-1220

  Devitt, Emma ^a,b   Lawless, Matthew W ^a   Sadlier, Denise ^b   A Browne, John ^a   Walsh, Caroline ^a   Crowe, John ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

early viral response; gene expression; hepatitis C; pegylated interferon; ribavirin; viral kinetics

Indexed keywords

G PROTEIN COUPLED RECEPTOR 30; INTERFERON; METALLOTHIONEIN II; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEIN IFIT2; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 6; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HEPATITIS C; HUMAN; MALE; MICROARRAY ANALYSIS; MOLECULAR GENETICS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENE EXPRESSION PROFILING; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; TIME FACTORS;

EID: 77957572533     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32833caf7b     Document Type: Article

References (41)

1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999;6:35-47.
2. Di Bisceglie AM. Hepatitis C. Lancet 1998;351:351-355.
3. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36(5 Suppl 1):S35-S46.
4. Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006;130:225-230.
5. Chung RT, Gale M Jr, Polyak SJ, Lemon SM, Liang TJ, Hoofnagle JH. Mechanisms of action of interferon and ribavirin in chronic hepatitis C: summary of a workshop. Hepatology 2008;47:306-320.
6. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-1492.
7. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-1171.
8. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-1374.
9. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010;138:2307-2314.
10. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide assocatiation of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nature Genetics 2009;41:1105-1109.
11. Pearlman BL. Chronic hepatitis C therapy: changing the rules of duration. Clin Gastroenterol Hepatol 2006;4:963-971.
12. Davis GL. Tailoring antiviral therapy in hepatitis C. Hepatology 2006;43:909-911.
13. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103.
14. Karino Y, Toyota J, Sugawara M, Higashino K, Sato T, Ohmura T, et al. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C. Am J Gastroenterol 1997;92:61-65.
15. Carlsson T, Reichard O, Norkrans G, Blackberg J, Sangfelt P, Wallmark E, Weiland O. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. J Viral Hepat 2005;12:473-480.
16. Neumann AU, Bain VG, Yoshida EM, Patel K, Pulkstenis E, Subramanian GM. Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C. Liver Int 2009;29:1350-1355.
17. Nomura H, Miyagi Y, Tanimoto H, Higashi M, Ishibashi H. Effective prediction of outcome of combination therapy with pegylated interferon alpha 2b plus ribavirin in Japanese patients with genotype-1 chronic hepatitis C using early viral kinetics and new indices. J Gastroenterol 2009;44:338-345.
18. Bosotti R, Locatelli G, Healy S, Scacheri E, Sartori L, Mercurio C, et al. Cross platform microarray analysis for robust identification of differentially expressed genes. BMC Bioinformatics 2007;8(Suppl 1):S5.
19. Berzsenyi MD, Roberts SK, Beard MR. Genomics of hepatitis B and C infections: diagnostic and therapeutic applications of microarray profiling. Antivir Ther 2006;11:541-552.
20. Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 2007;46:1548-1563.
21. Rainer J, Sanchez-Cabo F, Stocker G, Sturn A, Trajanoski Z. CARMAweb: comprehensive R-and bioconductor-based web service for microarray data analysis. Nucleic Acids Res 2006;34(Web Server issue):W498-W503.
22. Larionov A, Krause A, Miller W. A standard curve based method for relative real time PCR data processing. BMC Bioinformatics 2005;6:62.
23. Quackenbush J. Microarray data normalization and transformation. Nat Genet 2002;32(Suppl):496-501.
24. Fellenberg K, Hauser NC, Brors B, Neutzner A, Hoheisel JD, Vingron M. Correspondence analysis applied to microarray data. Proc Natl Acad Sci U S A 2001;98:10781-10786.
25. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-14868.
26. Taylor MW, Tsukahara T, Brodsky L, Schaley J, Sanda C, Stephens MJ, et al. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol 2007;81:3391-3401.
27. Ji X, Cheung R, Cooper S, Li Q, Greenberg HB, He XS. Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology 2003;37:610-621.
28. Younossi ZM, Baranova A, Afendy A, Collantes R, Stepanova M, Manyam G, et al. Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon-alfa and ribavirin. Hepatology 2009;49:763-774.
29. Nagamine T, Suzuki K, Kondo T, Nakazato K, Kakizaki S, Takagi H, Nakajima K. Interferon-alpha-induced changes in metallothionein expression in liver biopsies from patients with chronic hepatitis C. Can J Gastroenterol 2005;19:481-486.
30. Carrera G, Paternain JL, Carrere N, Folch J, Courtade-Saidi M, Orfila C, et al. Hepatic metallothionein in patients with chronic hepatitis C: relationship with severity of liver disease and response to treatment. Am J Gastroenterol 2003;98:1142-1149.
31. Bureau C, Bernad J, Chaouche N, Orfila C, Béraud M, Gonindard C, et al. Nonstructural 3 protein of hepatitis C virus triggers an oxidative burst in human monocytes via activation of NADPH oxidase. J Biol Chem 2001;276:23077-23083.
32. Nagamine T, Suzuki K, Kondo T, Nakazato K, Kakizaki S, Takagi H, Nakajima K. Interferon-alpha-induced changes in metallothionein expression in liver biopsies from patients with chronic hepatitis C. Can J Gastroenterol 2005;19:481-486.
33. Bonecchi R, Galliera E, Borroni EM, Corsi MM, Locati M, Mantovani A. Chemokines and chemokine receptors: an overview. Front Biosci 2009;14:540-551.
34. Ray RB, Meyer K, Steele R, Shrivastava A, Aggarwal BB, Ray R. Inhibition of tumor necrosis factor (TNF-alpha)-mediated apoptosis by hepatit C virus core protein. J Biol Chem 1998;273:225609.
35. Yarilina A, Ivashkiv LB. Type I Interferon: a new player in TNF signaling. Curr Dir Autoimmun 2010;11:94-104.
36. Berchtold S, Manncke B, Klenk J, Geisel J, Autenrieth IB, Bohn E. Forced IFIT-2 expression represses LPS induced TNF-alpha expression at posttranscriptional levels. BMC Immunol 2008;9:75.
37. Asselah T, Benhamou Y, Marcellin P. Protease and polymerase inhibitors for the treatment of hepatitis C. Liver Int 2009;29(Suppl 1):57-67.
38. Kronenberger B, Zeuzem S. Current and future treatment options for HCV. Ann Hepatol 2009;8:103-112.
39. Kronenberger B, Zeuzem S. Treatment of chronic hepatitis C: anticipated impact of resistance in patients treated with protease inhibitors. Curr Gastroenterol Rep 2009;11:15-21.
40. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-1838.
41. Thompson AJ, McHutchison JG. Antiviral resistance and specifically targeted therapy for HCV (STAT-C). J Viral Hepat 2009;16:377-387.